Bringing identification of empirically supported treatments into the 21st century.

Chambless, Dianne L.

doi:10.1111/cpsp.12128

Cited by 10 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The original criteria for empirically-supported treatments proposed by Chambless and Hollon (1998) were selected over more recent criteria (e.g., proposed by Tolin, McKay, Forman, Klonsky, & Thombs, 2015). As newer criteria have been criticised (for a full commentary, see Chambless, 2015), and the Chambless and Hollon (1998) criteria are still the most commonly implemented in psychological treatment research (e.g., Steinert, Munder, Rabung, Hoyer, & Leichsenring, 2017), we used the original criteria for establishing the empirical status of the third-wave therapies.…”

mentioning

confidence: 99%

The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review

Linardon

Fairburn

Fitzsimmons‐Craft

et al. 2017

Clinical Psychology Review

183

122

View full text Add to dashboard Cite

Although third-wave behaviour therapies are being increasingly used for the treatment of eating disorders, their efficacy is largely unknown. This systematic review and meta-analysis aimed to examine the empirical status of these therapies. Twenty-seven studies met full inclusion criteria. Only 13 randomized controlled trials (RCT) were identified, most on binge eating disorder (BED). Pooled within- (pre-post change) and between-groups effect sizes were calculated for the meta-analysis. Large pre-post symptom improvements were observed for all third-wave treatments, including dialectical behaviour therapy (DBT), schema therapy (ST), acceptance and commitment therapy (ACT), mindfulness-based interventions (MBI), and compassion-focused therapy (CFT). Third-wave therapies were not superior to active comparisons generally, or to cognitive-behaviour therapy (CBT) in RCTs. Based on our qualitative synthesis, none of the third-wave therapies meet established criteria for an empirically supported treatment for particular eating disorder subgroups. Until further RCTs demonstrate the efficacy of third-wave therapies for particular eating disorder subgroups, the available data suggest that CBT should retain its status as the recommended treatment approach for bulimia nervosa (BN) and BED, and the front running treatment for anorexia nervosa (AN) in adults, with interpersonal psychotherapy (IPT) considered a strong empirically-supported alternative.

show abstract

mentioning

confidence: 99%

The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review

Linardon

Fairburn

Fitzsimmons‐Craft

et al. 2017

Clinical Psychology Review

183

122

View full text Add to dashboard Cite

show abstract

“…Importantly, the amount of time and cost required for training is one of the largest barriers to the dissemination of empirically supported treatments for emotional disorders in low- and middle-income countries (Cuijpers et al, 2019; Murray et al, 2014), in addition to the complex comorbidity present in most patients that are not easily addressed with treatment protocols designed for a single diagnosis (Chambless, 2015; Stewart et al, 2012). Instead of addressing co-occurring conditions sequentially, and thereby extending the length of treatment, UP simultaneously address symptoms of multiple disorders by targeting the core, underlying processes that maintain comorbidity (Sauer-Zavala et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Changes in neuroticism-related constructs over the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in patients on an optimal dose of SSRI.

Zemestani

Ommati

Rezaei

et al. 2022

Personality Disorders: Theory, Research, and Treatment

View full text Add to dashboard Cite

Recent advances in clinical practice emphasize the utility of Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) as an effective intervention for targeting core processes underlying comorbid disorders. This study aimed to evaluate changes in psychopathological risk factors associated with the construct of neuroticism (i.e., negative affect, anxiety sensitivity, experiential avoidance, intolerance of uncertainty) within the UP to adults already on an optimal and stable dose of SSRIs. In a randomized controlled trial, a total of 39 adults (M age = 27.51 [68.43]; 56.4% female) on SSRIs with a diagnosis of comorbid anxiety and depressive disorder were randomly assigned to either UP þ SSRI (n = 18) or continued SSRI-only (n = 21). Neuroticism dimensions were assessed at baseline, posttreatment, and 1-month follow-up. UP þ SSRI condition demonstrated medium to large effect sizes for changes over time on facets of neuroticism including negative affect (Cohen's d = 1.12, 95% confidence interval [CI; 0.44, 1.80]), anxiety sensitivity (Cohen's d = 1.21, 95% CI [0.53, 1.90]), experiential avoidance (Cohen's d = 0.74, 95% CI [0.09, 1.04]), and intolerance of uncertainty (Cohen's d = 1.66, 95% CI [0.93, 2.39]). Post hoc analyses showed reductions in variables that were maintained at followup. Results adds to the growing body of literature and provide cross-cultural support for the utility of UP in targeting pathological risk factors as adjuncts to SSRI. Implications for future studies and limitations are discussed.

show abstract

“…To that end, behavioral therapies research has provided concrete guidelines as to what elements are required at each stage of treatment development and how those steps can be integrated into research proposals (Rounsaville et al, 2001). This approach is highly consistent with the technology model of behavioral therapy and has implications for how these therapies are later evaluated for the strength of the evidence of their efficacy (i.e., evidence-based treatments approach) (Chambless, 2015).…”

Section: Introductionmentioning

confidence: 90%

Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder

Ray

Bujarski

Roche

et al. 2018

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

As the development of novel pharmacotherapies for alcohol use disorder (AUD) has been slow, the discovery and testing of more efficacious pharmacotherapies for AUD represent a high priority research area. In fact, the transition from preclinical to clinical testing of novel compounds has been termed the "valley of death" in medications development. One key obstacle consists of the lack of an articulated set of goals for each stage of medications development. Specifically, the knowledge outputs required to make the transition from safety testing, to early efficacy detection, to confirming clinical efficacy remain unclear, and this is despite a great deal of interest and substantial financial investment in developing novel therapeutics for AUD. This qualitative critical review seeks to draw parallels and lessons from the well-established stage model for behavioral therapies research with alcohol and other substance use disorders and to apply these insights into AUD pharmacotherapy development. We argue that human laboratory models and/or pilot randomized controlled trials should serve as intermediaries in the transition from preclinical studies to large, and costly, randomized controlled efficacy trials. The relative strengths and weaknesses of pilot clinical trials versus human laboratory studies for bridging the "valley of death" are discussed and explored via a Monte Carlo data simulation study. Multiple permutations of suitable research designs informed by the behavioral therapies development model are discussed with the overall goal of promoting consilience and maximizing efficiency across all phases of clinical testing of novel AUD pharmacotherapies.

show abstract

Bringing identification of empirically supported treatments into the 21st century.

Cited by 10 publications

References 4 publications

The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review

The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review

Changes in neuroticism-related constructs over the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in patients on an optimal dose of SSRI.

Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder

Contact Info

Product

Resources

About